EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis

Marcin Miszczyk, Tamás Fazekas, Paweł Rajwa, Akihiro Matsukawa, Ichiro Tsuboi, Michael S Leapman, Gero Kramer, Maha Hussain, Axel Merseburger, Alberto Briganti, Anthony V D'Amico, Silke Gillessen und 2 weitere

European Urology Focus · 2025-09 · 11 (5) · 755-766

DOI: 10.1016/j.euf.2025.03.019 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Urology Focus, 2025-09. Verfasst von Marcin Miszczyk und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum, Faculty of Medicine, WSB Univer…. Hauptthemen laut MEDLINE: Prostate-Specific Antigen, Prostatic Neoplasms, Androgen Receptor Antagonists, Androgen Antagonists. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Narodowa Agencja Wymiany Akademickiej, Agencja Badań Medycznych.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: For patients with advanced prostate cancer (PC) treated with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI), the decline in prostate-specific antigen (PSA) is a potential biomarker for treatment response. We synthesised data regarding the association of the PSA response with overall survival (OS). METHODS: The MEDLINE, Embase, Web of Science, and Google Scholar databases were searched up to November 2024 to identify studies evaluating the association between the PSA response and OS among patients treated with ADT + ARPI. Hazard ratios (HRs) were pooled in random-effects meta-analyses. KEY FINDINGS AND LIMITATIONS: We identified 14 studies comprising a total of 8883 patients. Among four studies in metastatic hormone-sensitive PC (n = 2197), achievement of an undetectable PSA level was associated with better OS (HR 0.33, 95% confidence interval [CI] 0.23-0.49). In two studies in nonmetastatic castration-resistant PC (n = 1507), a PSA decline to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostate-Specific AntigenProstatic NeoplasmsAndrogen Receptor AntagonistsAndrogen AntagonistsHumansMalePrognosisSurvival Rate

Stichwörter der Autor:innen

Androgen deprivation therapyAndrogen receptor pathway inhibitorAndrogen receptor–targeted agentHormonal therapyNovel hormonal agentProstate-specific antigen

Substanzen

Prostate-Specific AntigenAndrogen Receptor AntagonistsAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Collegium Medicum, Faculty of Medicine, WSB University, Dąbrowa Górnicza, Poland.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Semmelweis University, Budapest, Hungary.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Division of Surgery and Interventional Sciences, University College London, London, UK; Second Department of Urology, Ce…
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Shimane University Faculty of Medicine, Shimane, Japan; Department of Urology, Okayama University…
  • Department of Urology, Yale University School of Medicine, New Haven, CT, USA.

Förderung

  • Narodowa Agencja Wymiany Akademickiej
  • Agencja Badań Medycznych

Zitieren

APA

Miszczyk, M., Fazekas, T., Rajwa, P., Matsukawa, A., Tsuboi, I., Leapman, M. S., Kramer, G., Hussain, M., Merseburger, A., Briganti, A., D'Amico, A. V., Gillessen, S., Saad, F., & Shariat, S. F. (2025). Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus, 11(5), 755-766. https://doi.org/10.1016/j.euf.2025.03.019

Vancouver

Miszczyk M, Fazekas T, Rajwa P, Matsukawa A, Tsuboi I, Leapman MS, et al. Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis. European Urology Focus. 2025;11(5):755-766. doi:10.1016/j.euf.2025.03.019

BibTeX
@article{Miszczyk2025,
  author = {Miszczyk, Marcin and Fazekas, Tamás and Rajwa, Paweł and Matsukawa, Akihiro and Tsuboi, Ichiro and Leapman, Michael S and Kramer, Gero and Hussain, Maha and Merseburger, Axel and Briganti, Alberto and D'Amico, Anthony V and Gillessen, Silke and Saad, Fred and Shariat, Shahrokh F},
  title = {Prostate-specific Antigen Response as a Prognostic Factor for Overall Survival in Patients with Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors: A Systematic Review and Meta-analysis},
  journal = {European Urology Focus},
  year = {2025},
  volume = {11},
  number = {5},
  pages = {755--766},
  doi = {10.1016/j.euf.2025.03.019}
}
Kostenlos starten →